Cartesian Therapeutics (RNAC) AI Stock Analysis

• Market Cap: $212.44M
• Dividend Yield: N/A
• Average Volume (3M): 79.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.50
• Shares Outstanding: 26,002,043
• 10 Day Avg. Volume: 83,590
• 30 Day Avg. Volume: 79,917
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 124.57
• Enterprise Value/Gross Profit: 124.57
• Enterprise Value/Ebitda: -1.68
• 1Y Price Target: $40.20
• Price Target Upside: 392.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 40 Underperform
• Price Target: $9.50 ▲(16.28% Upside)

The overall stock score is primarily driven by significant financial challenges, including declining revenues, negative equity, and weak cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and approaching oversold conditions. The negative P/E ratio and lack of dividend yield further weigh on the valuation, resulting in a low overall score.

Positive Factors

Innovative Platform

The company's proprietary RNA-based platform provides a competitive edge in developing targeted therapies, addressing unmet medical needs in neurology and oncology, which could lead to long-term growth opportunities.

Partnership Revenue Model

The partnership-driven revenue model ensures a steady stream of funding for R&D and potential milestone payments, supporting sustainable cash flow and reducing financial risk associated with product development.

Inducement Award

The inducement award reflects strategic hiring and retention efforts, potentially enhancing talent acquisition and retention, which is crucial for innovation and long-term success in the biotechnology sector.

Negative Factors

Declining Revenues

The drastic decline in revenues indicates challenges in monetizing the company's technology and products, which could impact future growth and financial stability if not addressed.

Negative Equity

Negative equity suggests financial instability, limiting the company's ability to raise capital and invest in growth opportunities, potentially hindering long-term strategic initiatives.

Weak Cash Flows

Weak cash flows indicate operational inefficiencies and financial strain, which could limit the company's ability to fund R&D and other critical activities necessary for long-term success.

Cartesian Therapeutics Business Overview & Revenue Model

Company Description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Cartesian Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. These partnerships often involve funding for research and development activities, as well as milestone payments associated with the advancement of therapeutic candidates through clinical trials. Additionally, the company may receive royalties on future sales of products developed through these collaborations. The potential for licensing agreements also represents a significant revenue stream, as Cartesian Therapeutics seeks to monetize its proprietary technologies and therapeutic candidates.

Cartesian Therapeutics Financial Statement Overview

Summary

Cartesian Therapeutics is facing significant financial challenges. The income statement reflects declining revenues and high operational losses, while the balance sheet shows negative equity, suggesting financial instability. Cash flow statements highlight cash outflows and dependency on external financing, raising concerns about the company's long-term sustainability.

Income Statement

Cartesian Therapeutics shows a concerning trend in profitability, with a negative TTM net profit margin of -112.1% and a declining revenue trend. The gross profit margin remains high at 99.4% in the TTM, but the company struggles with negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's balance sheet is weak, highlighted by a negative stockholders' equity of -$21.79 million in the TTM, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative. These factors point to potential liquidity issues and high leverage risk, despite having substantial cash reserves.

Cash Flow

Cartesian Therapeutics has a negative free cash flow in the TTM of -$40.43 million, indicating cash outflow concerns. The operating cash flow to net income ratio shows operational cash drain, reflecting inefficiencies. However, significant financing cash flow suggests reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	38.91M	26.00M	110.78M	85.08M	16.60M
Gross Profit	1.03M	38.91M	24.45M	108.74M	85.08M	16.60M
EBITDA	-75.92M	-77.14M	-235.06M	39.84M	-5.16M	-65.59M
Net Income	-36.26M	-77.42M	-219.71M	35.38M	-25.69M	-68.88M
Balance Sheet
Total Assets	388.89M	435.02M	305.05M	165.89M	159.88M	165.44M
Cash, Cash Equivalents and Short-Term Investments	160.32M	212.61M	76.91M	134.60M	128.06M	138.69M
Total Debt	13.35M	13.98M	10.96M	37.92M	35.28M	35.35M
Total Liabilities	391.42M	441.82M	745.23M	72.06M	137.36M	183.44M
Stockholders Equity	-2.53M	-6.80M	-440.18M	93.83M	22.52M	-18.01M
Cash Flow
Free Cash Flow	-44.51M	-32.77M	-51.37M	-32.83M	-61.47M	34.07M
Operating Cash Flow	-33.94M	-23.67M	-51.16M	-31.63M	-60.38M	34.88M
Investing Cash Flow	-10.22M	-8.74M	34.61M	-15.00M	-17.14M	-741.00K
Financing Cash Flow	117.31M	168.43M	-13.14M	39.22M	52.90M	14.43M

Cartesian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Negative. The current price of 8.17 is below the 20-day moving average (MA) of 9.21, below the 50-day MA of 9.73, and below the 200-day MA of 12.54, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 35.39 is Neutral, neither overbought nor oversold. The STOCH value of 17.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAC.

Cartesian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	―	$256.89M	5.20	63.24%	―	8.63%	429.84%
DBVT	―	$510.93M	―	-234.58%	―	―	1.29%
VYGR	―	$259.04M	―	-37.26%	―	-70.38%	-683.06%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVIR	―	$257.91M	―	-32.38%	―	―	23.24%
RNAC	―	$212.44M	-0.16	―	―	―	―
VOR	―	$164.94M	―	―	―	―	-686.12%

Cartesian Therapeutics Corporate Events

Cartesian Therapeutics’ Descartes-08: A Promising Phase 3 Trial for Myasthenia Gravis

Cartesian Therapeutics, Inc. is conducting a Phase 3 clinical trial titled ‘A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.’ The study aims to evaluate the safety, tolerability, and efficacy of Descartes-08, an investigational mRNA CAR T-cell therapy, in treating generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder.

Cartesian Therapeutics Advances Autoimmune Disorder Treatment with Descartes-08 Study

Cartesian Therapeutics, Inc. is spearheading a clinical study titled ‘DESCARTES-08 FOR CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH AUTOIMMUNE DISORDERS.’ The study aims to evaluate the safety, tolerability, and efficacy of Descartes-08 in young individuals suffering from autoimmune conditions like childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. This research holds significant promise for improving treatment options for these challenging conditions.

Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study

Study Overview: Cartesian Therapeutics, Inc. is conducting a Phase II study titled Descartes-08 for Patients With Systemic Lupus Erythematosus to evaluate the safety, tolerability, and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systemic Lupus Erythematosus (SLE). This study is significant as it explores innovative treatments for SLE, a chronic autoimmune disease with limited effective therapies.

Cartesian Therapeutics Eliminates Chief Scientific Officer Role

On October 15, 2025, Cartesian Therapeutics, Inc. announced the elimination of the Chief Scientific Officer position, leading to the termination of Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell entered into a separation agreement on October 20, 2025, which includes severance payments and benefits in exchange for releasing any claims against the company, reflecting a strategic shift in the company’s operations.

The most recent analyst rating on (RNAC) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.

Cartesian Therapeutics Appoints New Chief Accounting Officer

On October 2, 2025, Cartesian Therapeutics appointed June Seymour as Chief Accounting Officer, effective October 27, 2025. Ms. Seymour brings extensive financial leadership experience from her previous roles at DNAnexus, Neogene Therapeutics, and Autolus Ltd. Her appointment includes a comprehensive employment agreement outlining her salary, bonuses, and stock options, as well as non-compete and non-solicitation clauses. This strategic hire is expected to enhance the company’s financial operations and strengthen its position in the life sciences industry.

The most recent analyst rating on (RNAC) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering cell therapy for the treatment of autoimmune diseases, utilizing its proprietary technology and manufacturing platform to enhance cell function. The company aims to provide deep, durable clinical benefits to patients with autoimmune diseases through outpatient-administered therapies without the need for pre-treatment chemotherapy.